Cellular Pathology - Andrology
Andrology
The laboratory's priority is to provide a comprehensive semen analysis service for Consultants, Urologists and General Practitioners from the Birmingham and Solihull area. This includes semen analysis (Diagnostic Semen Analysis), post-operative analysis of semen following a vasectomy operation (Post Vasectomy Semen Analysis) and Retrograde analysis of urine.
The laboratory operates on a clinic based service and has a maximum capacity of 2000 appointments available per annum. This covers the annual workload of routine diagnostic semen analysis, post-vasectomy samples and retrograde ejaculation analysis. Routinely patients will be given an appointment to attend the Andrology Department for on-site sample production in a designated private clinic room, however in exceptional circumstances samples may be produced off site if then able to be delivered to the laboratory within an appropriate time interval.
The UHB Andrology Laboratory has fully trained scientists who are highly proficient in performing quality diagnostic semen analysis in line with World Health Organisation (2021) and the 2016 Laboratory Guidelines for post vasectomy semen analysis. The laboratory regularly performs internal quality control, participates in the UK National External Quality Assurance Reproductive scheme for Andrology (UKNEQAS) and liaises with other accredited laboratories for comparison of tests not covered within the UKNEQAS scope.
A laboratory referral can be made via:
- Paper copy referral forms sent to Appointment Centre via post/e-mail
- Electronic Referral Service (e-RS) with an attached referral form
A copy of the referral form can be obtained by;
- Contacting the laboratory directly on 0121 424 9717 Or by accessing the word version at:
Andrology referrals
Off-site production can be arranged by the patient by telephoning the laboratory on 0121 424 9717 or by e-mailing
Turnaround Time: 7-10 days (electronic reporting may be more rapid). Paper copies sent out following result authorisation.
Anti-sperm antibodies (ASAB) are not tested at this laboratory. Agglutination is described if noted.
Accreditation information can be found under Cellular Pathology (UKAS 10141):
https://www.ukas.com/download-schedule/10141/Medical/
Post-vasectomy Semen Analysis (PVSA)
The laboratory undertakes examination procedures in line with the following guidelines: 2016 PVSA Guidelines. This will give clinicians information regarding clearance criteria.
Results are available to Hospital clinicians via PICS, Clinical Portal, and ICE.
GP’s can access patient results through their own electronic result systems.
Key details of the service:
- Operates Monday to Friday 08:00am to 16:00pm
- Undertakes Diagnostic semen analysis, Post vasectomy semen analysis and Retrograde examination (urine)
- Appointment based with on-site private room for sample production
- 7-10 day turnaround time (electronic and paper copy reporting)
- Patients are booked within 7 weeks from referral, unless clinically indicated or by patient choice
Please see user handbook for additional information including contact details:
Andrology User Handbook
Andrology - Measurement Uncertainty
Following on from our recent UKAS assessment, we were advised that we need to demonstrate that the clinical impact of the Measurement of Uncertainty on clinical decision values has been assessed and considered in relation to patient outcome. This must include an explanation of any effects this could have to the decision limits and how they should be interpreted.
Diagnostic Semen Analysis
Application of the Coefficient of Variation (CV) to the Clinical Relevance of Diagnostic Semen Analysis (DSA)
The pooled coefficient of variation (CV%) was calculated for each diagnostic semen analysis parameter from the preceding 12 months of Internal Quality Control (IQC) data. The pooled CV was derived using the pooled standard deviation and the overall mean result for each parameter, providing an estimate of the laboratory's analytical imprecision. Expanded measurement uncertainty was calculated using a coverage factor of k = 2, representing an approximate 95% level of confidence.
The expanded relative uncertainty for each parameter is shown below:
|
Parameter |
CV |
Expanded Relative Uncertainty (%) |
|
Motility |
8.56 |
17.12 |
|
Concentration |
18.20 |
36.41 |
|
Morphology |
22.14 |
44.27 |
|
Vitality |
12.83 |
25.65 |
The uncertainty associated with an individual patient result is calculated by multiplying the reported result by the expanded relative uncertainty and dividing by 100. The reported result therefore has an associated reportable range of the reported value ± the calculated uncertainty.
The following examples demonstrate how the expanded relative uncertainty is applied to individual patient results to calculate the expanded uncertainty and corresponding reportable range:
|
Parameter |
Example Result |
Calculated Uncertainty |
Reported Range |
|
Motility |
30% |
±5.1% |
24.9–35.1% |
|
Concentration |
16 × 10⁶/mL |
±5.8 × 10⁶/mL |
10.2–21.8 × 10⁶/mL |
|
Morphology |
4% |
±1.8% |
2.2–5.8% |
|
Vitality |
54% |
±13.9% |
40.1–67.9% |
Measurement uncertainty is particularly important when results are close to established clinical decision limits. In these circumstances, the associated uncertainty should be considered when interpreting results alongside the patient's clinical history and other relevant investigations.
Information regarding the laboratory's measurement uncertainty is communicated to service users through annual updates to the laboratory website. Internal users of the service, including the Fertility and Urology teams, are informed directly by email
Post Vasectomy Semen Analysis
To ensure compliance with the clearance levels of the 2016 post vasectomy guidelines (<100, 000 sperm/ml) the laboratory have ensured that sperm can be detected in samples that contain 3,507.5 sperm/ml (as ascertained through multiple dilutions).
Retrograde Analysis
Retrograde samples have multiple factors that can influence the uncertainty of the results. The laboratory has established a limit of detection for sperm of 37.66 sperm/ml.
Clinical Impact of Measurement Uncertainty
Measurement uncertainty, either for one reported parameter or as a combination of multiple reported parameters could have a clinical impact. For example, if a concentration of 15 x 10⁶/ml is reported (oligozoospermia), given a UoM of 1.4 x 10⁶/ml, this sample could have a concentration of 16 x 10⁶/ml (normozoospermia).
For some users, a diagnosis of oligozoospermia, even at the borderline level of 15 x 10⁶/ml, could lead to the recommendation of an assisted reproductive technology such as intracytoplasmic sperm injection (ICSI) to promote the chance of fertilisation, when conventional IVF, or even natural conception, might be possible.
We inform our users of this uncertainty and emphasize that the reports can be used to guide clinicians to determine how to proceed with further investigation and management of a subfertile couple. We stress that all reported parameters should be considered holistically.
Furthermore, as per WHO 2021 guidance, we inform users that many known and unknown female factors hamper the value of using only semen examination parameters to predict the prognosis for the couple of spontaneous or assisted fertilization.
The decision limits that we provide on our reports are derived from WHO 2021 and are derived from data characterizing the semen characteristics of a reference population (men whose partners had a time to pregnancy of 12 months or less). The data uses a diverse international populations, noting that the percentiles used do not represent distinct limits between fertile and subfertile men.
We highlight that a semen analysis is never prognostic of fertility, as it is the fertility potential of the couple that defines them as fertile or subfertile.
Department of Cellular Pathology
- Created on .
- Last updated on .
- Hits: 37450






